Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).

Trial Profile

Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Gallium 68-DOTATATE (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors Advanced Accelerator Applications
  • Most Recent Events

    • 01 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top